Toxicity
toxicity, skin rash, skin toxicity, rash
ADVERSE EVENTS, SKIN TOXICITY
GC1118 was generally well tolerated except for skin toxicity; none of patients experienced a Grade 4 treatment‐related AE. Treatment‐related AE profiles for all patients (Treatment‐related adverse events (AEs).Skin toxicity was the most frequent AE: 76.2% of patients (16/21) experienced skin rash of at least Grade 1. Grade 2 skin toxicity was found in nine patients, and Grade 3 skin rash was noted in four patients; these four patients needed treatment interruption including dose reduction or skipped dosages.The main cause of dose reduction was skin toxicity; GC1118 was reduced to 3 mg/kg in six patients and 2 mg/kg in two patients. Two patients (SMC‐0002 and SNUH‐008) were hospitalized because of skin rash attributed to GC1118. SMC‐0002 patient maintained the treatment with dose reduction and intermittent dose omission, while SNUH‐008 patient was dropped out due to three consecutively missed drug dosages.